<p>藥明康德（NASDAQ:BMRN - 獲取免費報告）的股票在週二由 Wedbush 重新發布了 “跑贏大盤” 的評級，RTT 新聞報道。他們目前對這家生物技術公司的股票設定了 94.00 美元的目標價。Wedbush 的目標價意味着該股票當前價格有 51.02% 的潛在上漲空間。</p>
<ul>
<li>藥明康德的股票能否滿足華爾街的高期望？</li>
</ul>
<p>其他一些股票研究分析師最近也對該股票發佈了報告。Wolfe Research 在 7 月 15 日的研究報告中對藥明康德的股票設定了 95.00 美元的價格目標，並給予公司 “跑贏大盤” 的評級。Wall Street Zen 在 7 月 18 日的研究報告中將藥明康德的股票評級從 “強力買入” 下調至 “買入”。高盛集團在 5 月 5 日的研究報告中將藥明康德的股票目標價從 124.00 美元下調至 104.00 美元，並給予公司 “買入” 評級。摩根士丹利在 7 月 22 日的報告中將藥明康德的目標價從 97.00 美元下調至 96.00 美元，並給予公司 “增持” 評級。最後，摩根大通在 7 月 14 日的研究報告中將藥明康德的股票目標價從 108.00 美元上調至 113.00 美元，並給予該股票 “增持” 評級。六位股票研究分析師對該股票給予了持有評級，十九位分析師給予公司買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 93.78 美元。</p>
<p><strong>獲取我們對 BMRN 的最新股票分析</strong></p>
<h2>藥明康德的價格表現</h2>
<ul>
<li>3 只超賣股票具有大幅反彈潛力</li>
</ul>
<p>週二，BMRN 的交易價格上漲了 1.93 美元，達到 62.24 美元。該股票的交易量為 1,233,643 股，而其平均交易量為 1,887,433 股。該公司的市值為 119.4 億美元，市盈率為 23.21，市盈率/增長比率為 0.80，貝塔值為 0.18。藥明康德的 1 年最低價為 52.93 美元，1 年最高價為 94.85 美元。該公司的債務與股本比率為 0.10，流動比率為 5.52，速動比率為 3.49。該公司的 50 日移動平均價格為 57.16 美元，200 日移動平均價格為 61.79 美元。</p>
<h2>藥明康德的內部交易</h2>
<p>在相關消息中，首席會計官 Erin Burkhart 在 5 月 20 日的交易中出售了 1,786 股藥明康德的股票。該股票以平均價格 59.31 美元出售，總交易額為 105,927.66 美元。出售完成後，首席會計官持有該公司 14,173 股股票，價值 840,600.63 美元。此次交易使其持股減少了 11.19%。該交易已在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。內部人士持有該公司 0.85% 的股票。</p>
<h2>機構資金流入和流出</h2>
<ul>
<li>基因治療股票會成為市場下一個大贏家嗎？</li>
</ul>
<p>一些對沖基金最近買入和賣出了該公司的股票。Rise Advisors LLC 在第一季度購買了藥明康德的新頭寸，價值 30,000 美元。Farther Finance Advisors LLC 在第一季度將其在藥明康德的股份增加了 95.9%。Farther Finance Advisors LLC 現在擁有 431 股該生物技術公司的股票，價值 29,000 美元，此前在該期間又購買了 211 股。V Square Quantitative Management LLC 在第二季度購買了藥明康德的新頭寸，價值約 25,000 美元。LRI Investments LLC 在第四季度將其在藥明康德的股份增加了 856.9%。LRI Investments LLC 現在擁有 488 股該生物技術公司的股票，價值 32,000 美元，此前在上個季度又購買了 437 股。最後，MassMutual Private Wealth &amp; Trust FSB 在第一季度將其在藥明康德的股份增加了 71.2%。MassMutual Private Wealth &amp; Trust FSB 現在擁有 524 股該生物技術公司的股票，價值 37,000 美元，此前在該期間又購買了 218 股。98.71% 的股票目前由機構投資者持有。</p>
<h2>關於藥明康德</h2>
<p>（獲取免費報告）</p>
<p>藥明康德公司開發和商業化針對嚴重和危及生命的罕見疾病及醫療狀況的治療方案。其商業產品包括 Vimizim，一種用於治療粘多糖貯積症（MPS）IV 型 A 的酶替代療法；Naglazyme，一種用於 MPS VI 患者的重組 N-乙酰半乳糖胺 4-硫酸酶；以及 Kuvan，一種用於治療苯丙酮尿症（PKU）患者的專有合成口服 6R-BH4。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過藥明康德</li>
<li>國會股票交易跟蹤</li>
<li>Figma 的瘋狂 IPO 之旅：股票的溢價價格是否合理？</li>
<li>現在購買的 3 只沃倫·巴菲特股票</li>
<li>META 獲得巨大升級：分析師認為股票可能上漲多少</li>
<li>投資旅遊股票的好處</li>
<li>諾和諾德股票下跌——但是否終於觸底？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
<p>在考慮藥明康德之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而拜瑪林製藥並不在名單上。</p>
<p>雖然拜瑪林製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

拜瑪林制藥

<p>Wedbush 重申了對拜瑪林製藥（BioMarin Pharmaceutical，股票代碼：BMRN）的 “跑贏大盤” 評級，目標價為 94.00 美元，意味着潛在上漲空間為 51.02%。其他分析師也給出了評級，Wolfe Research 設定了 95.00 美元的目標價，高盛則將其調整至 104.00 美元。該股票目前交易價格為 62.24 美元，市場共識評級為 “適度買入”，平均目標價為 93.78 美元。拜瑪林專注於罕見疾病的治療，市值為 119.4 億美元</p>

<p>BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report)'s stock had its &#34;outperform&#34; rating reissued by Wedbush in a note issued to investors on Tuesday,RTT News reports. They presently have a $94.00 target price on the biotechnology company's stock. Wedbush's target price points to a potential upside of 51.02% from the stock's current price.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:BMRN - 獲取免費報告）的股票在週二由 Wedbush 重新發布了 “跑贏大盤” 的評級，RTT 新聞報道。他們目前對這家生物技術公司的股票設定了 94.00 美元的目標價。Wedbush 的目標價意味着該股票當前價格有 51.02% 的潛在上漲空間。</p>
</div><ul>
<li>Can BioMarin Stock Live Up to Wall Street’s High Expectations?</li>
</ul>
<div class="lb-trans"><ul>
<li>藥明康德的股票能否滿足華爾街的高期望？</li>
</ul>
</div><p>A number of other equities research analysts also recently issued reports on the stock. Wolfe Research set a $95.00 price objective on shares of BioMarin Pharmaceutical and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, July 15th. Wall Street Zen cut shares of BioMarin Pharmaceutical from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Friday, July 18th. The Goldman Sachs Group dropped their price target on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, May 5th. Morgan Stanley reduced their target price on BioMarin Pharmaceutical from $97.00 to $96.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, July 22nd. Finally, JPMorgan Chase &amp; Co. increased their price objective on shares of BioMarin Pharmaceutical from $108.00 to $113.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, July 14th. Six equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $93.78.</p>
<div class="lb-trans"><p>其他一些股票研究分析師最近也對該股票發佈了報告。Wolfe Research 在 7 月 15 日的研究報告中對藥明康德的股票設定了 95.00 美元的價格目標，並給予公司 “跑贏大盤” 的評級。Wall Street Zen 在 7 月 18 日的研究報告中將藥明康德的股票評級從 “強力買入” 下調至 “買入”。高盛集團在 5 月 5 日的研究報告中將藥明康德的股票目標價從 124.00 美元下調至 104.00 美元，並給予公司 “買入” 評級。摩根士丹利在 7 月 22 日的報告中將藥明康德的目標價從 97.00 美元下調至 96.00 美元，並給予公司 “增持” 評級。最後，摩根大通在 7 月 14 日的研究報告中將藥明康德的股票目標價從 108.00 美元上調至 113.00 美元，並給予該股票 “增持” 評級。六位股票研究分析師對該股票給予了持有評級，十九位分析師給予公司買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 93.78 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on BMRN</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 BMRN 的最新股票分析</strong></p>
</div><h2>BioMarin Pharmaceutical Price Performance</h2>
<div class="lb-trans"><h2>藥明康德的價格表現</h2>
</div><ul>
<li>3 Oversold Stocks with Big RSI Rebound Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只超賣股票具有大幅反彈潛力</li>
</ul>
</div><p>BMRN traded up $1.93 during trading on Tuesday, reaching $62.24. 1,233,643 shares of the stock were exchanged, compared to its average volume of 1,887,433. The company has a market capitalization of $11.94 billion, a price-to-earnings ratio of 23.21, a P/E/G ratio of 0.80 and a beta of 0.18. BioMarin Pharmaceutical has a 1 year low of $52.93 and a 1 year high of $94.85. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.52 and a quick ratio of 3.49. The business's 50 day moving average price is $57.16 and its two-hundred day moving average price is $61.79.</p>
<div class="lb-trans"><p>週二，BMRN 的交易價格上漲了 1.93 美元，達到 62.24 美元。該股票的交易量為 1,233,643 股，而其平均交易量為 1,887,433 股。該公司的市值為 119.4 億美元，市盈率為 23.21，市盈率/增長比率為 0.80，貝塔值為 0.18。藥明康德的 1 年最低價為 52.93 美元，1 年最高價為 94.85 美元。該公司的債務與股本比率為 0.10，流動比率為 5.52，速動比率為 3.49。該公司的 50 日移動平均價格為 57.16 美元，200 日移動平均價格為 61.79 美元。</p>
</div><h2>Insider Transactions at BioMarin Pharmaceutical</h2>
<div class="lb-trans"><h2>藥明康德的內部交易</h2>
</div><p>In related news, CAO Erin Burkhart sold 1,786 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the sale, the chief accounting officer owned 14,173 shares of the company's stock, valued at $840,600.63. The trade was a 11.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.85% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席會計官 Erin Burkhart 在 5 月 20 日的交易中出售了 1,786 股藥明康德的股票。該股票以平均價格 59.31 美元出售，總交易額為 105,927.66 美元。出售完成後，首席會計官持有該公司 14,173 股股票，價值 840,600.63 美元。此次交易使其持股減少了 11.19%。該交易已在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。內部人士持有該公司 0.85% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><ul>
<li>Are Gene Therapy Stocks The Market's Next Big Winners?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因治療股票會成為市場下一個大贏家嗎？</li>
</ul>
</div><p>A number of hedge funds have recently bought and sold shares of the company. Rise Advisors LLC purchased a new position in BioMarin Pharmaceutical during the first quarter valued at $30,000. Farther Finance Advisors LLC grew its stake in BioMarin Pharmaceutical by 95.9% during the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after buying an additional 211 shares during the period. V Square Quantitative Management LLC bought a new position in BioMarin Pharmaceutical in the 2nd quarter valued at about $25,000. LRI Investments LLC boosted its stake in shares of BioMarin Pharmaceutical by 856.9% in the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 437 shares in the last quarter. Finally, MassMutual Private Wealth &amp; Trust FSB lifted its position in BioMarin Pharmaceutical by 71.2% during the 1st quarter. MassMutual Private Wealth &amp; Trust FSB now owns 524 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 218 shares during the period. 98.71% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金最近買入和賣出了該公司的股票。Rise Advisors LLC 在第一季度購買了藥明康德的新頭寸，價值 30,000 美元。Farther Finance Advisors LLC 在第一季度將其在藥明康德的股份增加了 95.9%。Farther Finance Advisors LLC 現在擁有 431 股該生物技術公司的股票，價值 29,000 美元，此前在該期間又購買了 211 股。V Square Quantitative Management LLC 在第二季度購買了藥明康德的新頭寸，價值約 25,000 美元。LRI Investments LLC 在第四季度將其在藥明康德的股份增加了 856.9%。LRI Investments LLC 現在擁有 488 股該生物技術公司的股票，價值 32,000 美元，此前在上個季度又購買了 437 股。最後，MassMutual Private Wealth &amp; Trust FSB 在第一季度將其在藥明康德的股份增加了 71.2%。MassMutual Private Wealth &amp; Trust FSB 現在擁有 524 股該生物技術公司的股票，價值 37,000 美元，此前在該期間又購買了 218 股。98.71% 的股票目前由機構投資者持有。</p>
</div><h2>About BioMarin Pharmaceutical</h2>
<div class="lb-trans"><h2>關於藥明康德</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.</p>
<div class="lb-trans"><p>藥明康德公司開發和商業化針對嚴重和危及生命的罕見疾病及醫療狀況的治療方案。其商業產品包括 Vimizim，一種用於治療粘多糖貯積症（MPS）IV 型 A 的酶替代療法；Naglazyme，一種用於 MPS VI 患者的重組 N-乙酰半乳糖胺 4-硫酸酶；以及 Kuvan，一種用於治療苯丙酮尿症（PKU）患者的專有合成口服 6R-BH4。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than BioMarin Pharmaceutical</li>
<li>Following Congress Stock Trades</li>
<li>Figma's Wild IPO Ride: Is the Stock's Premium Price Justified?</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>META Gets Huge Upgrades: How High Analysts Think Shares Could Go</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過藥明康德</li>
<li>國會股票交易跟蹤</li>
<li>Figma 的瘋狂 IPO 之旅：股票的溢價價格是否合理？</li>
<li>現在購買的 3 只沃倫·巴菲特股票</li>
<li>META 獲得巨大升級：分析師認為股票可能上漲多少</li>
<li>投資旅遊股票的好處</li>
<li>諾和諾德股票下跌——但是否終於觸底？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BMRN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
</div><p>Before you consider BioMarin Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮藥明康德之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而拜瑪林製藥並不在名單上。</p>
</div><p>While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然拜瑪林製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Wedbush 重申對 BioMarin Pharmaceutical（BMRN）的 “跑贏大盤” 評級